skip to main content

Our M&A lawyers are among the most experienced and effective in the world. We represent many of the world's largest publicly traded and privately held companies, as well as leading private equity firms, hedge funds, financial advisors and other financial institutions and investors on their most important merger, acquisitions and takeover transactions.

Alexion Pharmaceuticals to Acquire Portola Pharmaceuticals

Paul, Weiss is advising Alexion Pharmaceuticals, Inc. in its acquisition of Portola Pharmaceuticals Inc., a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders. Under the terms of the transaction, Alexion will acquire all of Portola’s outstanding shares at $18 per share in cash. The deal is expected to close in the third quarter of 2020, subject to customary closing conditions and regulatory approvals.

The Paul, Weiss team includes corporate partners Rachael Coffey, Scott Barshay, Caith Kushner, John Kennedy and Raphael Russo; intellectual property partner Jonathan Ashtor; employee benefits partner Jean McLoughlin; litigation partners Rick Rule, Eric Stone and Jaren Janghorbani and counsel Rachel Fiorill; tax partner Robert Holo; real estate partner Peter Fisch; and antitrust counsel Yuni Sobel and Marta Kelly

May 5, 2020

© 2021 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy